Manuel J Richter1, Natascha Sommer2, Ralph Schermuly2, Birk Grimminger2, Werner Seeger2, Khodr Tello2, Hossein A Ghofrani3, Henning Gall4. 1. Department of Pneumology, Kerckhoff Heart and Thoracic Center, Bad Nauheim, Germany; Department of Internal Medicine, Justus Liebig University Giessen, and Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Germany, Giessen, Germany. 2. Department of Internal Medicine, Justus Liebig University Giessen, and Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Germany, Giessen, Germany. 3. Department of Pneumology, Kerckhoff Heart and Thoracic Center, Bad Nauheim, Germany; Department of Internal Medicine, Justus Liebig University Giessen, and Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Germany, Giessen, Germany; Department of Medicine, Imperial College London, London, United Kingdom. 4. Department of Internal Medicine, Justus Liebig University Giessen, and Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Germany, Giessen, Germany. Electronic address: henning.gall@innere.med.uni-giessen.de.
Abstract
BACKGROUND: Thyroid disease is common in patients with pulmonary hypertension (PH), but its effect on long-term survival remains unknown. We examined the prognostic significance of thyroid hormone levels of free triiodothyronine (fT3) and free thyroxine and thyroid-stimulating hormone (TSH), and thyroid hormone replacement (THR) therapy in PH. METHODS: We conducted a retrospective analysis of 1,756 patients enrolled in the Giessen PH Registry in 1999 to 2013 with baseline thyroid function data; of these, 355, 533, 498, and 370 had pulmonary arterial hypertension (PAH); including 192 with idiopathic PAH (iPAH), PH due to left heart disease, PH due to lung diseases, and chronic thromboembolic PH (CTEPH), respectively. Thyroid function parameters associated with mortality were identified using Cox regression and Kaplan-Meier analyses. RESULTS: Transplant-free survival at 1, 3, and 5 years was 86.7%, 65.6%, and 53.0%, respectively. Absence of THR therapy was an independent predictor of death in iPAH (multivariate hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.06-5.75). In patients without THR therapy, TSH levels in the lowest and highest quartiles (compared with the middle 2 quartiles) independently predicted death in iPAH (HR, 1.98; 95% CI, 1.07-3.67), whereas reduced fT3 levels were independently associated with increased death in PAH (HR, 8.30; 95% CI, 2.50-25.00) and CTEPH (HR, 1.79; 95% CI, 1.14-4.20). CONCLUSIONS: Thyroid hormone levels and THR therapy are prognostic factors in iPAH, PAH, and CTEPH. Prospective studies are warranted to verify the prognostic significance of thyroid function and the effect of THR therapy in PH. Copyright Â
BACKGROUND:Thyroid disease is common in patients with pulmonary hypertension (PH), but its effect on long-term survival remains unknown. We examined the prognostic significance of thyroid hormone levels of free triiodothyronine (fT3) and free thyroxine and thyroid-stimulating hormone (TSH), and thyroid hormone replacement (THR) therapy in PH. METHODS: We conducted a retrospective analysis of 1,756 patients enrolled in the Giessen PH Registry in 1999 to 2013 with baseline thyroid function data; of these, 355, 533, 498, and 370 had pulmonary arterial hypertension (PAH); including 192 with idiopathic PAH (iPAH), PH due to left heart disease, PH due to lung diseases, and chronic thromboembolic PH (CTEPH), respectively. Thyroid function parameters associated with mortality were identified using Cox regression and Kaplan-Meier analyses. RESULTS: Transplant-free survival at 1, 3, and 5 years was 86.7%, 65.6%, and 53.0%, respectively. Absence of THR therapy was an independent predictor of death in iPAH (multivariate hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.06-5.75). In patients without THR therapy, TSH levels in the lowest and highest quartiles (compared with the middle 2 quartiles) independently predicted death in iPAH (HR, 1.98; 95% CI, 1.07-3.67), whereas reduced fT3 levels were independently associated with increased death in PAH (HR, 8.30; 95% CI, 2.50-25.00) and CTEPH (HR, 1.79; 95% CI, 1.14-4.20). CONCLUSIONS: Thyroid hormone levels and THR therapy are prognostic factors in iPAH, PAH, and CTEPH. Prospective studies are warranted to verify the prognostic significance of thyroid function and the effect of THR therapy in PH. Copyright Â
Authors: Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez Journal: Am J Respir Crit Care Med Date: 2020-01-15 Impact factor: 21.405
Authors: Valentina Mercurio; Grace Peloquin; Khalil I Bourji; Nermin Diab; Takahiro Sato; Blessing Enobun; Traci Housten-Harris; Rachel Damico; Todd M Kolb; Stephen C Mathai; Ryan J Tedford; Carlo G Tocchetti; Paul M Hassoun Journal: Pulm Circ Date: 2018-03-26 Impact factor: 3.017
Authors: Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Grzegorz Kopeć; Olga Dzikowska-Diduch; Ewa Mroczek; Tatiana Mularek-Kubzdela; Łukasz Chrzanowski; Ilona Skoczylas; Michał Tomaszewski; Małgorzata Peregud-Pogorzelska; Danuta Karasek; Ewa Lewicka; Wojciech Jacheć; Zbigniew Gąsior; Piotr Błaszczak; Katarzyna Ptaszyńska-Kopczyńska; Katarzyna Mizia-Stec; Andrzej Biederman; Dariusz Zieliński; Roman Przybylski; Piotr Kędzierski; Marcin Waligóra; Marek Roik; Marek Grabka; Joanna Orłowska; Aleksander Araszkiewicz; Marta Banaszkiewicz; Sylwia Sławek-Szmyt; Szymon Darocha; Wojciech Magoń; Alicja Dąbrowska-Kugacka; Jakub Stępniewski; Kamil Jonas; Karol Kamiński; Jarosław D Kasprzak; Piotr Podolec; Piotr Pruszczyk; Adam Torbicki; Marcin Kurzyna Journal: Ther Adv Chronic Dis Date: 2021-03-25 Impact factor: 5.091
Authors: Hongyang Pi; Samuel G Rayner; David D Ralph; Stephanie Nolley; Lia M Barros; Zachary L Steinberg; Peter J Leary Journal: BMJ Open Respir Res Date: 2022-07